# Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

> **NCT04055090** · PHASE3 · COMPLETED · sponsor: **Helixmith Co., Ltd.** · enrollment: 101 (actual)

## Conditions studied

- Painful Diabetic Neuropathy
- Diabetic Neuropathy, Painful

## Interventions

- **GENETIC:** Long-Term Follow-Up of Patients who Received Engensis (VM202)
- **DRUG:** Long-Term Follow-Up of Patients who Received Placebo

## Key facts

- **NCT ID:** NCT04055090
- **Lead sponsor:** Helixmith Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-04
- **Primary completion:** 2019-07-24
- **Final completion:** 2019-07-24
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055090, "Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04055090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*